Adjuvant Therapy in Colorectal Cancer: Aspirin, a Targeted Therapy?

作者：Sibertin Blanc C; Dahan L; Michel P; Seitz J F^*

来源：Oncologie, 2014, 16(11-12): S509-S515.

DOI：10.1007/s10269-014-2463-2

• Colorectal cancer
• Aspirin
• Adjuvant therapy
• PIK3CA mutation
• COX-2

Despite the efficacy of adjuvant chemotherapy in colorectal cancer (CRC), almost half of all patients who undergo surgical resection with curative intent will experience relapse. It remains a necessity to find an adjuvant therapy that is more effective. Regular use of aspirin reduces the risk of CRC and adenoma%26apos;s development. This antineoplastic effect is partially due to inhibition of PIK3/AKT pathway through COX-2 inhibition. Two recent retrospective studies suggested that regular use of aspirin after CRC diagnosis improves survival and decreases the risk of recurrence in patients with PIK3CA-mutated tumour, but it was not confirmed in a recent study. Aspirin could be active as a targeted therapy. However, the adverse events, particularly in older patients, could limit its use in routine clinical practice. A prospective randomized evaluation is required after the resection of CRC with PIK3CA mutation.

• 出版日期2014-12